A globally First-in-class autologous CAR-T product developed based on the CD24 target.

Target Advantages

· The CD24 protein has a complex structure,

presenting high barriers to research and development, and the product is highly innovative;

· CD24 is broadly expressed on multiple types of malignant tumor cells,making the product applicable to a wide range of indications；

Safety

· Designed using specific antibodies that recognize only tumor tissues and not normal tissues, the product has no tissue cross-reactivity and high safety.

CD24 is not expressed on red blood cells, thus the therapy does not cause anemia as a side effect.

Efficacy

· The CAR-T therapy, targeted against CD24, has shown the ability to completely eliminate tumor cells in ovarian cancer solid tumor models. This indicates a significant potential for effective treatment of solid tumors, particularly in ovarian cancer.

This therapy brings new hope for patients with recurrent ovarian epithelial cancer!